Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus

View through CrossRef
Background Kaposiform hemangioendothelioma (KHE) is a vascular tumor frequently associated with Kasabach–Merritt phenomenon (KMP), characterized by severe thrombocytopenia and consumptive coagulopathy. Visceral involvement in KHE is rare. In our recent experience, sirolimus has shown to be an effective treatment in cutaneous KHE, becoming indeed the treatment of choice in KMP. We report a case of pancreatic KHE associated with KMP and refractory to sirolimus. Case Report A 4-month-old infant is referred for obstructive jaundice (10 mg/dL conjugated bilirubin) secondary to vascular pancreatic tumor. Magnetic resonance (MR) and immunohistochemistry were compatible with KHE, but the tumor was considered unresectable. We initiated sirolimus (0.8 mg/m2/12 h) to treat KMP, and interventional radiology was performed for percutaneous biliary diversion. This procedure prompted KMP (platelets: 51,000/µL). Sirolimus treatment for 7 days showed no effect; therefore, we started our VAT protocol (vincristine/aspirine/ticlopidin) with great response after 10 days (platelets: 3,70,000/µL). Three months later, percutaneous biliary diversion was replaced by a biliary stent. The tumor disappeared leaving fibrosis and dilatation of biliary tract needing hepaticojejunostomy 6 months later. Discussion It is difficult to establish protocols for an unusual presentation of a tumor with different targets. This is a reason collaborative multicenter studies should be performed. Management of obstructive jaundice secondary to a tumor that usually regresses in 10 years is an added challenge; therefore, the management should be led by a multidisciplinary team.Sirolimus treatment in cutaneous KHE has been described as successful in the literature, as well as in our own experience; however, it failed in our first patient with visceral KHE. We need to investigate the different response to pharmacological agents in tumors with similar histopathology, but with visceral involvement.
Title: Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus
Description:
Background Kaposiform hemangioendothelioma (KHE) is a vascular tumor frequently associated with Kasabach–Merritt phenomenon (KMP), characterized by severe thrombocytopenia and consumptive coagulopathy.
Visceral involvement in KHE is rare.
In our recent experience, sirolimus has shown to be an effective treatment in cutaneous KHE, becoming indeed the treatment of choice in KMP.
We report a case of pancreatic KHE associated with KMP and refractory to sirolimus.
Case Report A 4-month-old infant is referred for obstructive jaundice (10 mg/dL conjugated bilirubin) secondary to vascular pancreatic tumor.
Magnetic resonance (MR) and immunohistochemistry were compatible with KHE, but the tumor was considered unresectable.
We initiated sirolimus (0.
8 mg/m2/12 h) to treat KMP, and interventional radiology was performed for percutaneous biliary diversion.
This procedure prompted KMP (platelets: 51,000/µL).
Sirolimus treatment for 7 days showed no effect; therefore, we started our VAT protocol (vincristine/aspirine/ticlopidin) with great response after 10 days (platelets: 3,70,000/µL).
Three months later, percutaneous biliary diversion was replaced by a biliary stent.
The tumor disappeared leaving fibrosis and dilatation of biliary tract needing hepaticojejunostomy 6 months later.
Discussion It is difficult to establish protocols for an unusual presentation of a tumor with different targets.
This is a reason collaborative multicenter studies should be performed.
Management of obstructive jaundice secondary to a tumor that usually regresses in 10 years is an added challenge; therefore, the management should be led by a multidisciplinary team.
Sirolimus treatment in cutaneous KHE has been described as successful in the literature, as well as in our own experience; however, it failed in our first patient with visceral KHE.
We need to investigate the different response to pharmacological agents in tumors with similar histopathology, but with visceral involvement.

Related Results

Sirolimus-Induced Pneumonitis Following Liver Transplantation
Sirolimus-Induced Pneumonitis Following Liver Transplantation
Abstract Sirolimus-induced pneumonitis has emerged as a potentially serious complication in renal transplantation but only single case re...
Sirolimus therapy in a child with partially diazoxide-responsive hyperinsulinaemic hypoglycaemia
Sirolimus therapy in a child with partially diazoxide-responsive hyperinsulinaemic hypoglycaemia
Summary Hyperinsulinaemic hypoglycaemia (HH), which causes persistent neonatal hypoglycaemia, can result in neurological damage and it’s management is challenging. Diazoxide is the...
Effective Management of Rare Lymphangioleiomyomatosis Using Sirolimus: Tablet Matrix with Hibiscus rosa sinensis Leave Mucilage
Effective Management of Rare Lymphangioleiomyomatosis Using Sirolimus: Tablet Matrix with Hibiscus rosa sinensis Leave Mucilage
The authors aimed to extend the discharge of Sirolimus from the tablets with a blend of herbal and synthetic polymers. In this study, Sirolimus was taken as a model drug, Hydroxy P...
Sirolimus PK trial: A pharmacokinetic study of the sirolimus‐eluting Bx Velocity stent in patients with de novo coronary lesions
Sirolimus PK trial: A pharmacokinetic study of the sirolimus‐eluting Bx Velocity stent in patients with de novo coronary lesions
AbstractThis study was conducted to assess the systemic drug release and distribution of sirolimus‐eluting stents. Early results with sirolimus‐eluting stents have demonstrated a f...
Health-Related Quality of Life following Sirolimus Treatment for Vascular Anomalies
Health-Related Quality of Life following Sirolimus Treatment for Vascular Anomalies
Objective: Sirolimus is a safe and effective pharmaceutical for the treatment of vascular anomalies (VAs); however, there are limited analyses of health-related quality...
Proliferative Cells From Kaposiform Lymphangiomatosis Lesions Resemble Mesenchyme Stem Cell–like Pericytes Defective in Vessel Formation
Proliferative Cells From Kaposiform Lymphangiomatosis Lesions Resemble Mesenchyme Stem Cell–like Pericytes Defective in Vessel Formation
Kaposiform lymphangiomatosis (KLA) is a vascular anomaly featuring lymphatic expansion. It has no known cause, no effective treatment, and is associated with high morbidity. Prolif...
Kasabach-Merritt Phenomenon in a 7-month-old Cambodian Infant
Kasabach-Merritt Phenomenon in a 7-month-old Cambodian Infant
Kasabach-Merritt phenomenon (KMP) is a rare condition associated with vascular tumors such as kaposiform hemangioendothelioma and tufted angioma; it can be life-threatening due to ...
Comparative Vascular Effects of Sirolimus and Everolimus on Isolated Human Saphenous Veins
Comparative Vascular Effects of Sirolimus and Everolimus on Isolated Human Saphenous Veins
Drug-eluting stents, which release antiproliferative agents such as sirolimus and everolimus, were developed to reduce the risk of restenosis associated with bare-metal stents. How...

Back to Top